TRAVERE THERAPEUTICS, INC. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9deff617-98ff-4c98-9348-f08fd314be50/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-62.8M | 2025-01-01 – 2025-12-31 | evidence 0001438533-26-000014 |
| FY 2024 | $-323.8M | 2024-01-01 – 2024-12-31 | evidence 0001438533-25-000010 |
| FY 2023 | $-388.1M | 2023-01-01 – 2023-12-31 | evidence 0001438533-24-000005 |
| FY 2022 | $-319.8M | 2022-01-01 – 2022-12-31 | evidence 0001438533-24-000005 |
| FY 2021 | $-199.4M | 2021-01-01 – 2021-12-31 | evidence 0001438533-24-000005 |
| FY 2020 | $-176.2M | 2020-01-01 – 2020-12-31 | evidence 0001438533-21-000008 |
| FY 2019 | $-137.4M | 2019-01-01 – 2019-12-31 | evidence 0001438533-20-000004 |
| FY 2018 | $-80.0M | 2018-01-01 – 2018-12-31 | evidence 0001438533-19-000003 |
| FY 2017 | $-53.8M | 2017-01-01 – 2017-12-31 | evidence 0001438533-18-000006 |
| FY 2016 | $-58.2M | 2016-01-01 – 2016-12-31 | evidence 0001438533-17-000005 |
| FY 2015 | $-50.7M | 2015-01-01 – 2015-12-31 | evidence 0001628280-16-011857 |
| FY 2014 | $-79.8M | 2014-01-01 – 2014-12-31 | evidence 0001628280-16-011857 |
| FY 2013 | $-24.8M | 2013-01-01 – 2013-12-31 | evidence 0001628280-16-011857 |
| FY 2012 | $-35.8M | 2011-03-11 – 2013-03-31 | evidence 0001193805-13-001332 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TRAVERE THERAPEUTICS, INC. — all facts · Revenue · Net Income